Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
GO:00525479 | Breast | Precancer | regulation of peptidase activity | 71/1080 | 461/18723 | 2.72e-14 | 6.94e-12 | 71 |
GO:00525489 | Breast | Precancer | regulation of endopeptidase activity | 67/1080 | 432/18723 | 1.06e-13 | 2.36e-11 | 67 |
GO:00064578 | Breast | Precancer | protein folding | 43/1080 | 212/18723 | 3.48e-13 | 7.45e-11 | 43 |
GO:20001169 | Breast | Precancer | regulation of cysteine-type endopeptidase activity | 43/1080 | 235/18723 | 1.30e-11 | 1.83e-09 | 43 |
GO:00432819 | Breast | Precancer | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 40/1080 | 209/18723 | 1.59e-11 | 2.07e-09 | 40 |
GO:20012349 | Breast | Precancer | negative regulation of apoptotic signaling pathway | 39/1080 | 224/18723 | 5.35e-10 | 4.77e-08 | 39 |
GO:00458619 | Breast | Precancer | negative regulation of proteolysis | 50/1080 | 351/18723 | 2.99e-09 | 2.39e-07 | 50 |
GO:00610778 | Breast | Precancer | chaperone-mediated protein folding | 19/1080 | 67/18723 | 4.22e-09 | 3.28e-07 | 19 |
GO:00513468 | Breast | Precancer | negative regulation of hydrolase activity | 50/1080 | 379/18723 | 3.85e-08 | 2.34e-06 | 50 |
GO:00104668 | Breast | Precancer | negative regulation of peptidase activity | 38/1080 | 262/18723 | 1.46e-07 | 7.82e-06 | 38 |
GO:00109519 | Breast | Precancer | negative regulation of endopeptidase activity | 37/1080 | 252/18723 | 1.55e-07 | 8.05e-06 | 37 |
GO:20001179 | Breast | Precancer | negative regulation of cysteine-type endopeptidase activity | 19/1080 | 86/18723 | 3.36e-07 | 1.58e-05 | 19 |
GO:19033629 | Breast | Precancer | regulation of cellular protein catabolic process | 36/1080 | 255/18723 | 6.03e-07 | 2.55e-05 | 36 |
GO:00421769 | Breast | Precancer | regulation of protein catabolic process | 47/1080 | 391/18723 | 1.50e-06 | 5.58e-05 | 47 |
GO:00431548 | Breast | Precancer | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 17/1080 | 78/18723 | 1.69e-06 | 6.08e-05 | 17 |
GO:19030509 | Breast | Precancer | regulation of proteolysis involved in cellular protein catabolic process | 31/1080 | 221/18723 | 4.10e-06 | 1.27e-04 | 31 |
GO:00313309 | Breast | Precancer | negative regulation of cellular catabolic process | 34/1080 | 262/18723 | 8.16e-06 | 2.20e-04 | 34 |
GO:19033638 | Breast | Precancer | negative regulation of cellular protein catabolic process | 14/1080 | 75/18723 | 8.54e-05 | 1.63e-03 | 14 |
GO:00098959 | Breast | Precancer | negative regulation of catabolic process | 36/1080 | 320/18723 | 9.92e-05 | 1.83e-03 | 36 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CSNK2A1 | SNV | Missense_Mutation | novel | c.161N>G | p.Phe54Cys | p.F54C | P68400 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CSNK2A1 | SNV | Missense_Mutation | | c.599N>T | p.Pro200Leu | p.P200L | P68400 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSNK2A1 | SNV | Missense_Mutation | novel | c.872A>G | p.His291Arg | p.H291R | P68400 | protein_coding | tolerated(0.14) | probably_damaging(0.999) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSNK2A1 | SNV | Missense_Mutation | | c.110A>T | p.Asp37Val | p.D37V | P68400 | protein_coding | deleterious(0) | possibly_damaging(0.825) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSNK2A1 | SNV | Missense_Mutation | | c.274N>A | p.Pro92Thr | p.P92T | P68400 | protein_coding | tolerated(0.27) | benign(0.009) | TCGA-D1-A16S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CSNK2A1 | SNV | Missense_Mutation | novel | c.964N>T | p.Pro322Ser | p.P322S | P68400 | protein_coding | deleterious(0.04) | benign(0.044) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
CSNK2A1 | SNV | Missense_Mutation | novel | c.347T>C | p.Val116Ala | p.V116A | P68400 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
CSNK2A1 | SNV | Missense_Mutation | novel | c.548N>G | p.His183Arg | p.H183R | P68400 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSNK2A1 | SNV | Missense_Mutation | novel | c.515G>A | p.Arg172Gln | p.R172Q | P68400 | protein_coding | deleterious(0) | possibly_damaging(0.613) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSNK2A1 | deletion | In_Frame_Del | novel | c.12_17delCGTGCC | p.Val5_Pro6del | p.V5_P6del | P68400 | protein_coding | | | TCGA-BD-A2L6-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1457 | CSNK2A1 | KINASE, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | 249565806 | SILMITASERTIB | |
1457 | CSNK2A1 | KINASE, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | CX-4945 | SILMITASERTIB | |
1457 | CSNK2A1 | KINASE, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | TAMATINIB | R-406 | |
1457 | CSNK2A1 | KINASE, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | 249565820 | | |
1457 | CSNK2A1 | KINASE, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | AZAKENPAULLONE | AZAKENPAULLONE | |
1457 | CSNK2A1 | KINASE, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | HEPARIN | HEPARIN | 7794926 |
1457 | CSNK2A1 | KINASE, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
1457 | CSNK2A1 | KINASE, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | MLN-8054 | MLN-8054 | |
1457 | CSNK2A1 | KINASE, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | SP-600125 | SP-600125 | |
1457 | CSNK2A1 | KINASE, TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | CYC-116 | CYC-116 | |